Drug Profile


Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator BioVex
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 01 Dec 2010 Discontinued - Preclinical for CNS disorders in United Kingdom (unspecified route)
  • 31 Aug 2009 Preclinical development is ongoing in UK
  • 09 Jan 2004 NeuroVEX has been licensed to Johnson&Johnson in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top